CCL18 has recently been implicated in malignancies and is increasingly mentioned as a potential tumoral biomarker and furtherly a molecular target for therapeutic intervention, but its expression and clinical significance in multiple myeloma have not been explored. Serum CCL18 levels were measured by ELISA method in 254 newly diagnosed multiple myeloma (NDMM), 21 monoclonal gammopathy of undetermined significance (MGUS) and 22 healthy adults. The study suggests that the serum CCL18 level in NDMM patients was significantly higher than that in MGUS and healthy adults. High level of CCL18 were associated with advanced ISS and R-ISS stages in MM. Patients with high serum CCL18 displayed a significantly more frequent occurrence of renal impairment and hypercalcemia, while the proportion of achieving complete remission (CR) was lower. More importantly, Cox analysis identified CCL18 and LDH as independent predictors of PFS in MM patients, whereas CCL18, creatinine and LDH were independent predictors of OS. Finally, we show that CCL18 can promote migration and invasion of myeloma cell lines RPMI8226 and MM.1S. CCL18 may play a tumor-promoting role by increasing the migration and invasion abilities of myeloma cells.

中文翻译：

---

CCL18 促进多发性骨髓瘤细胞的迁移和侵袭，并与不良预后相关。

CCL18 最近与恶性肿瘤有关，并越来越多地被提及为潜在的肿瘤生物标志物，并进一步成为治疗干预的分子靶点，但尚未探索其在多发性骨髓瘤中的表达和临床意义。采用 ELISA 法测定了 254 名新诊断的多发性骨髓瘤 (NDMM)、21 名意义未明的单克隆丙种球蛋白病 (MGUS) 和 22 名健康成人的血清 CCL18 水平。研究表明，NDMM 患者血清 CCL18 水平显着高于 MGUS 和健康成人。高水平的 CCL18 与 MM 中的晚期 ISS 和 R-ISS 阶段相关。血清CCL18高的患者肾功能损害和高钙血症的发生率明显更高，而达到完全缓解（CR）的比例更低。更重要的是，Cox 分析确定 CCL18 和 LDH 是 MM 患者 PFS 的独立预测因子，而 CCL18、肌酐和 LDH 是 OS 的独立预测因子。最后，我们表明 CCL18 可以促进骨髓瘤细胞系 RPMI8226 和 MM.1S 的迁移和侵袭。CCL18可能通过增加骨髓瘤细胞的迁移和侵袭能力发挥促瘤作用。